Epigenetic Regulation in Melanoma: Facts and Hopes

• Published in: Cells (Basel, Switzerland) Vol. 10; no. 8; p. 2048
• Main Authors: Giunta, Emilio Francesco, Arrichiello, Gianluca, Curvietto, Marcello, Pappalardo, Annalisa, Bosso, Davide, Rosanova, Mario, Diana, Anna, Giordano, Pasqualina, Petrillo, Angelica, Federico, Piera, Fabozzi, Teresa, Parola, Sara, Riccio, Vittorio, Mucci, Brigitta, Vanella, Vito, Festino, Lucia, Daniele, Bruno, Ascierto, Paolo Antonio, Ottaviano, Margaret
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 11-08-2021; MDPI
• Subjects: Chromatin remodeling; DNA methylation; Drug resistance; epigenetic drugs; Epigenetics; Immune checkpoint inhibitors; Immunosuppressive agents; Kinases; MAP kinase; Melanoma; Mutation; non-coding RNA; Patients; Review; Skin cancer
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells10082048

Cutaneous melanoma is a lethal disease, even when diagnosed in advanced stages. Although recent progress in biology and treatment has dramatically improved survival rates, new therapeutic approaches are still needed. Deregulation of epigenetics, which mainly controls DNA methylation status and chromatin remodeling, is implied not only in cancer initiation and progression, but also in resistance to antitumor drugs. Epigenetics in melanoma has been studied recently in both melanoma preclinical models and patient samples, highlighting its potential role in different phases of melanomagenesis, as well as in resistance to approved drugs such as immune checkpoint inhibitors and MAPK inhibitors. This review summarizes what is currently known about epigenetics in melanoma and dwells on the recognized and potential new targets for testing epigenetic drugs, alone or together with other agents, in advanced melanoma patients.